ogreogyg.osoyo1

Appl. No: 09/720,979 (U.S. National Stage of PCT/JP99/03552)

Atty. Dkt. No: 4001-0003

## Remarks

Entry of the above amendments to the specification is respectfully requested. The amendments incorporate the sequence identification numbers into the specification and thus, no new matter has been added. A marked-up version of page 7, lines 8-12, of the specification indicating the additions to the paragraph therein is attached hereto.

This application is now in condition for examination. If the Examiner has any questions or comments, the Examiner is requested to contact the undersigned at the telephone number below.

Respectfully submitted,

SHANKS & HERBERT

Reg. No. 41,448

Date: March 29, 2002

TransPotomac Plaza 1033 N. Fairfax Street Suite 306 Alexandria, VA 22314 (703) 683-3600

09220979.030701

Appl. No: 09/720,979

(U.S. National Stage of PCT/JP99/03552)

Atty. Dkt. No: 4001-0003



In the specification, paragraph on page 7, lines 8-12:

Figure 1 schematically shows a method for constructing the replication competent SeV comprising a foreign gene, such as for GFP or β-glucuronidase. Using primer 1 (SEQ ID NO:1), which has a *Not*I site, and primer 2 (SEQ ID NO:2), which comprises, a transcription termination signal (R2), an intervening sequence (IG), a transcription initiation sequence (R1) and a *Not*I site, the ORF of a foreign gene is amplified by PCR and inserted into the *Not*I site of pUC18/T7HVJRz.DNA (+18) (SEQ ID NO:3).